A detailed history of Advisor Group Holdings, Inc. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 470 shares of PTGX stock, worth $21,544. This represents 0.0% of its overall portfolio holdings.

Number of Shares
470
Previous 2,551 81.58%
Holding current value
$21,544
Previous $73,000 78.08%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$24.66 - $34.8 $51,317 - $72,418
-2,081 Reduced 81.58%
470 $16,000
Q1 2024

May 10, 2024

BUY
$21.79 - $32.15 $49,463 - $72,980
2,270 Added 807.83%
2,551 $73,000
Q4 2023

Feb 12, 2024

SELL
$14.05 - $23.44 $435 - $726
-31 Reduced 9.94%
281 $6,000
Q3 2023

Nov 13, 2023

BUY
$16.68 - $23.66 $5,204 - $7,381
312 New
312 $5,000
Q2 2022

Aug 10, 2022

SELL
$7.06 - $25.52 $402 - $1,454
-57 Closed
0 $0
Q3 2021

Nov 05, 2021

SELL
$12.95 - $49.69 $2,240 - $8,596
-173 Reduced 75.22%
57 $1,000
Q2 2021

Aug 02, 2021

BUY
$25.57 - $44.88 $946 - $1,660
37 Added 19.17%
230 $11,000
Q1 2021

May 13, 2021

SELL
$19.02 - $31.15 $18,373 - $30,090
-966 Reduced 83.35%
193 $5,000
Q4 2020

Feb 10, 2021

BUY
$18.49 - $25.13 $11,389 - $15,480
616 Added 113.44%
1,159 $24,000
Q3 2020

Nov 12, 2020

SELL
$15.19 - $22.4 $144,912 - $213,696
-9,540 Reduced 94.61%
543 $11,000
Q2 2020

Aug 14, 2020

BUY
$6.19 - $18.84 $61,900 - $188,400
10,000 Added 12048.19%
10,083 $178,000
Q1 2020

May 18, 2020

BUY
$5.4 - $9.22 $448 - $765
83 New
83 $1,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.